產(chǎn)品詳情
中文名稱:阿貝西利 | 英文名稱:Abemaciclib |
CAS:1231929-97-7 | 純度規(guī)格: 99%+ HPLC |
產(chǎn)品類別: 醫(yī)藥原料藥 |
2025-08-11
阿貝西利
Abemaciclib
5KG/RMB;25KG/RMB;100KG/RMB
99%+ HPLC
醫(yī)藥原料藥
通用名(中文):阿貝西利
通用名(英文):Abemaciclib
CAS No.:1231929-97-7
分子式:C27H32F2N8
分子量:506.59
外 觀:白色至黃色粉末。
用途:用于治療激素受體陽性且HER2陰性的早期乳腺癌、晚期或轉(zhuǎn)移性乳腺癌(國內(nèi)進(jìn)口原研)。
阿貝西利(abemaciclib)是美國禮來公司研發(fā)的一種口服有效的細(xì)胞周期蛋白依賴性激酶(cyclin-dependent kinases,CDKs)抑制劑,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)細(xì)胞周期通路,具有較好的抗腫瘤活性。該藥于2017年9月28日經(jīng)美國FDA批準(zhǔn)上市。
關(guān)鍵字: 1231929-97-7;阿貝西利;Abemaciclib;海步醫(yī)藥;
公司簡介
Beijing Hope Pharmaceutical Co., Ltd., established in 2005, is a high-tech enterprise with "chemical drug technology development-Process Optimization-Regulation registration and approval" as its core competence, and has won the title of "China Top 20 Pharmaceutical R&D Company" for several times. Hope Pharma actively builds one-stop service for drug CRO and CDMO, continuously expands its service areas, and establishes good cooperative relations with some leading pharmaceutical companies domestic and abroad.
Hope Pharma has over 20 years of experience in project evaluation, innovation-oriented patent around design, pre-clinical development, clinical trial practice, registration, marker authorization, etc..Our products involve anti-tumor, anti-depressant, anti-epileptic, anxiolytic, cardiovascular and cerebrovascular, digestive system, respiratory system and other indications.
Until now, more than 140 technology transform, over 90 registration approvals and 73 patents has been finished in Hope(including subsidiaries) for past 20 years, and has been rated as a national high-tech enterprise.
成立日期 |
2005-04-26
(21年)
|
注冊資本 |
4284.6849 萬元人民幣
|
員工人數(shù) |
100-500人 |
年營業(yè)額 |
¥ 1億以上 |
主營行業(yè) |
醫(yī)藥中間體,醫(yī)藥中間體,原料藥,原料藥 |
經(jīng)營模式 |
工廠,定制,工廠,定制 |